Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients

Prevalence and Risk Factors Associated With Resistance to Antiviral Therapy in Egyptian Patients With Chronic Hepatitis B Virus Infection

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07274345

Acronym

PRARE-CHB

Enrollment

2000

Registered

2025-12-10

Start date

2025-12-01

Completion date

2026-12-01

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection

Brief summary

This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors. Understanding patterns of resistance will help improve treatment selection and optimize long-term management strategies for HBV patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* This study will include all chronic HBV-infected patients, either cirrhotic or not, receiving TDF 300 mg, ETV 0.5 or 1mg, or lamivudine 100 mg, irrespective of HBeAg status. The HBV chronicity is defined by persistence of HbsAg positivity for more than 6 months.

Exclusion criteria

* Patients younger than 18 years old.

Design outcomes

Primary

Measure	Time frame
Proportion of Patients Exhibiting Antiviral Resistance Detection of HBV Antiviral Resistance Mutations	6 months

Contacts

Primary ContactAmira Mohamed Zidan

amira_mohamed_post@med.sohag.edu.eg201122884060

Outcome results